Recent Surge in FDA Approvals Shakes up the Oncology Promotional Landscape. Perjeta. Stivarga. Marquibo. Bosulif. Xtandi. Krypolis.
|
|
- Christina Cain
- 5 years ago
- Views:
Transcription
1 Krypolis Bosulif Inlyta Erivedge Xtandi Stivarga Alimta Gleevec Marquibo Perjeta Synribo Zaltrap Recent Surge in FDA Approvals Shakes up the Oncology Promotional Landscape By Bill Bowman, JD What a year 2012 has been. So far this year, the FDA has approved ten new brands for cancer treatment and eight supplemental applications were cleared for existing products. Much of this activity has occurred since the onset of summer, including eight new brands and four supplemental applications. Table 1 provides a summary of 2012 year-to-date FDA activity. NOVEMBER 2012 ONCBIZ.COM ONCOLOGY BUSINESS REVIEW 1
2 Recent Surge in FDA Approvals Shakes up the Oncology Promotional Landscape This rapid influx of so many new agents has dramatically altered the level of promotional activity, as companies vie for increasingly limited face time with busy oncologists. Further, the FDA approved six new oncologic products in 2011 and granted sndas for two more. The net effect of all these recent product launches is a fiercely competitive marketplace that can shift dramatically on a monthly basis. OBR has collaborated with ImpactRx to evaluate the changing promotional landscape due to the rollout of all these new brands. ImpactRx employs a proprietary database of 425 practicing oncologists equipped with iphones/ipads, enabling physicians to enter information on company representative visits at the point of engagement. This mobile research model provides both a marketplace view in real time and longitudinal tracking of changes in oncologists attitudes and behaviors. ImpactRx tapped into this database of approximately 3,000 monthly representative visits (including sales representatives, medical science liaisons, clinical study coordinators, and reimbursement specialists) with oncologists to determine which brands are being discussed most frequently. In order to assess the most up-todate impact of these new product approvals, we will first focus on promotional activity for the month of September 2012 and compare it with activity for the prior month, based on the number of representative visits. Later, we will compare September 2012 with September 2011 and assess longer-term trends going back to Table 1. Oncology Product Approvals Approvals (New Molecules) Brand Company Indication(s) Approval Date Synribo Teva Chronic Myeloid Leukemia October 26, 2012 Stivarga Bayer Metastatic Colorectal Cancer September 27, 2012 Bosulif P zer Chronic Myeloid Leukemia September 4, 2012 Xtandi Marqibo Medivation/ Astellas Talon Castration-Resistant Prostate Cancer Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia August 31, 2012 August 9, 2012 Zaltrap Sano Metastatic Colorectal Cancer August 3, 2012 Kyprolis Onyx Multiple Myeloma July 20, 2012 Perjeta Genentech HER2+ Metastatic Breast Cancer June 28, 2012 Erivedge Genentech Metastatic Basal Cell Carcinoma January 30, 2012 Inlyta P zer Advanced Renal Cell Carcinoma January 27, 2012 Alimta Lilly New Indication/Label Updates Label updated to include PFS data for maintenance therapy following 1 st line therapy in nonsquamous NSCLC October 17, 2012 Abraxane Celgene Non-small Cell Lung Cancer October 12, 2012 A nitor Erbitux Novartis Lilly/BMS Advanced HR+/HER2 Breast Cancer 1 st Line Metatstatc KRAS Mutation Negative Colorectal Cancer (with FOLFIRI) July 20, 2012 July 9, 2012 Votrient GSK Advanced Soft Tissue Sarcoma April 26, 2012 A nitor Novartis Renal angiomyolipoma associated with tuberous sclerosis complex (TSC) April 26, 2012 Gleevec Novartis Adjuvant therapy in Kit+ GIST January 31, 2012 Velcade (Sub-Q) Millennium New Formulation When Table 2 is compared to the earlier table listing new product approvals, we quickly note that three of the brands in the Top 10 list (Xtandi, Kyprolis and Multiple Myeloma/ Mantle Cell Lymphoma January 24, ONCOLOGY BUSINESS REVIEW ONCBIZ.COM NOVEMBER 2012
3 Zaltrap) were approved since this past summer. In particular, Xtandi (indicated for castration resistant prostate cancer) has quickly captured second place behind the reigning leader Afinitor, which was also recently cleared for marketing of advanced hormone receptor-positive/her2 negative breast cancer. Zaltrap (metastatic colorectal cancer) is also rapidly gaining on the leaders. Erbitux remained in the Top 10 in spite of the activity generated by these new arrivals, perhaps owing to its recently approved sbla for first-line treatment of KRAS mutation negative mcrc. This is not surprising, as breast, prostate and colorectal are big tumors where one would expect a high volume of promotional activity. Yet, Kyprolis (multiple myeloma) and Jakafi (myelofibrosis; approved in November 2011) target less common malignancies and each of these made the Top 10. [Note: Stivarga (also approved for metastatic colorectal cancer) did not make the September list due to its late breaking approval that month and Abraxane was just cleared for its new indication in advanced NSCLC.] If we take this analysis a step further and compare promotional activity for September 2012 versus September 2011, more striking differences are noted (Table 3). Most of the leaders from a year ago no longer appear in the current Top 10 list. The cytotoxic agent Jevtana (castration-resistant prostate cancer), in particular, has dropped from 4th to 44th position. This is undoubtedly based to a large extent on the launches of Zytiga and more recently Xtandi. Both of these brands are also indicated for castration-resistant prostate cancer and are also aiming to be used in the chemotherapy-naïve setting, which could further displace Jevtana. (Sanofi may have also moved resources from Jevtana to support its recent Zaltrap launch). Tasigna (CML) faces new competition from Bosulif (previously treated CML), which appeared on Table 2. Top 10 Oncology Brands Discussed by Company Representatives (September 2012) 2 Brand Sept 2012 Rank Change in Rank from Previous Month A nitor 1 No change Xtandi 2 N/A Xgeva 3 1 Kyprolis 4 3 Zaltrap 5 22 Alimta 6 3 Velcade 7 1 Jaka 8 10 Avastin 9 5 Erbitux 10 5 Joined the Top 10 in September How other new products fared in September: Perieta - 17th, Inlvta - 20th, Bosulif - 38th Table 3. Top 10 Oncology Brands Discussed by Company Representatives in September 2011: Where are they now? 3 Brand Sept 2011 Rank Sept 2012 Rank Xalkori 1 16 Xgeva 2 3 Alimta 3 6 Jevtana 4 44 Avastin 5 9 Erbitux 6 10 Tasigna 6 13 Sutent 8 24 Zytiga 9 15 Revlimid NOVEMBER 2012 ONCBIZ.COM ONCOLOGY BUSINESS REVIEW 3
4 Recent Surge in FDA Approvals Shakes up the Oncology Promotional Landscape the scene in early September The recent movement of Sutent to the 24th position may be due in part to the January 2012 approval of Inlyta, as both of these Pfizer brands are approved for advanced renal cell carcinoma and Inlyta is being targeted for pre-treated patients in a crowded market. (Some of Sutent s promotion is also directed at GIST and pancreatic neuroendocrine tumors/pnet). These brands joined the Top 10 list in September 2012: Xtandi Zaltrap Jakafi Other recently approved products reported a high level of promotional activity in September: Abraxane was already in 12th place prior to its October snda approval Perjeta ranked 17th Inlyta was in 20th position Bosulif appeared in 38th place (with less than a full month of data) Figure 1 shows representative promotional activity directed at oncologists since 2010 by quarters. If we look at these trends, it appears as if there has been only a modest increase in the average number of reported details for the first 3 quarters in 2012 compared with the first 3 quarters in 2011 (averaging 26.0 details per oncologist per quarter vs 24.0 per quarter, respectively). This upward tick may well be due to all the recent launch activity and any associated field force expansions. Yet, as multiple new products have come to market this year, one might expect a sharper increase in promotional activity than is shown here. Further, if we look back to the first 3 quarters of 2010, oncologists reported seeing 27.6 representatives per quarter, on average. This means that oncologists are not Figure 1. Oncology Representative Detailing Activity for All Promoted Brands (2010-Q3 2012) * 24.0* 26.0* Q Q Q Q Q Q Q Q Q Q Q Average No. Oncologists No. Details 10,105 10,031 9,882 8,022 9,131 9,163 8,892 9,252 10,263 9,627 9,178 * Average number of reported details per oncologist (Q1-Q3) 371 9,413 4 ONCOLOGY BUSINESS REVIEW ONCBIZ.COM NOVEMBER 2012
5 seeing more representatives, in spite of the rapid influx of so many brands. In fact, detail activity may have reached its peak, based on the overall downward trend seen since the first half of In other words, the volume of reported detailing activity has not kept pace with the ever growing armamentarium of oncology agents. These findings indicate that even with so many new launches, oncology representatives will face increased challenges in gaining entrée to see oncologists and promote their brands. Further, oncology practices are rapidly undergoing consolidation or are being acquired by hospitals in growing numbers. 5 These parallel trends in oncology practice business models can only exacerbate the increasingly fierce competition for critical face time with oncologists. In the months ahead, heightened competition and further shifts in promotional activity directed at oncologists can be expected, as more new products come to market (including Genentech s trastuzumab emtasine/t-dm1) and as the dust begins to settle for all recent entrants. References 1. FDA website: company press releases. 2. Internal ImpactRx analysis based on monthly longitudinal tracking data. 3. Ibid. 4. Internal ImpactRx analysis based on quarterly longitudinal tracking data. 5. Community Oncology Alliance, Practice Impact Report, April 4, About the Contributors Bill Bowman, JD is the Senior Manager of Product Management at ImpactRx. ImpactRx, a Symphony Health Solutions Company, is the leading provider of consultative and analytically-based promotional effectiveness solutions to the healthcare industry. ImpactRx specializes in measuring sales and marketing effectiveness in Oncologists offices. Powered by its longitudinal and normative data assets, ImpactRx s consulting analytics and custom research capabilities provide unparalleled insight into the dynamics of the Oncology marketplace. Through its i-enabled network of 425 targeted oncologists and its proprietary, state-of-the-art research technology, ImpactRx captures not only treatment decisions in response to promotion, but also the attitudes, perceptions and beliefs underlying those decisions. The integration of its comprehensive behavioral and attitudinal data with its innovative consulting analytics, global research expertise and therapeutic knowledge enables ImpactRx to deliver breakthrough solutions to its Oncology clients. These solutions empower clients to improve brand performance by making more informed and effective decisions around marketing strategy, field and channel execution and pre-launch and launch planning. For more information, visit NOVEMBER 2012 ONCBIZ.COM ONCOLOGY BUSINESS REVIEW 5
REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC476DFR PUBLICAT ION DATE NOVEMBER 2014 CYRAMZA (COLORECTAL CANCER) Executive Summary Table below presents the key metrics of Cyramza for colorectal cancer (CRC) in the eight major pharmaceutical
More informationClinical Therapeutic Intelligence Report: Year in Review
Clinical Therapeutic Intelligence Report: Year in Review Last year marked a productive year for oncology drug research and development with ten new oncology drugs coming to market two of which were granted
More informationREFERENCE CODE GDHC471DFR PUBLICAT ION DATE NOVEM BER 2014 VECTIBIX (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC471DFR PUBLICAT ION DATE NOVEM BER 2014 VECTIBIX (COLORECTAL CANCER) Executive Summary Table below presents the key metrics for Vectibix for colorectal cancer (CRC) in the eight major
More informationOpening Address: A Quick Survey Thinking 25 Years Backwards & Forwards
Opening Address: A Quick Survey Thinking 25 Years Backwards & Forwards Jeffrey M. Bockman, PhD Vice President Defined Health 24 th Annual Cancer Progress Conference March 4 th 5 th, 2014 March 4 th 5 th,
More informationREFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC472DFR PUBLICAT ION DATE NOVEM BER 2014 STIVARGA (COLORECTAL CANCER) Executive Summary Table below presents the key metrics for Stivarga for colorectal cancer (CRC) in the eight major
More informationREFERENCE CODE GDHC198DFR PUBLICAT ION DATE JUNE 2013 TARCEVA (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC198DFR PUBLICAT ION DATE JUNE 2013 TARCEVA (NON-SMALL CELL LUNG CANCER) Executive Summary Tarceva (erlotinib): Key Metrics in NSCLC Markets 2012 Tarceva Sales US 5EU Japan China India
More information08:FORECAST. The View From the Office: How Community Oncologists See 2008 By Peter Carlin and Don Stark of Market Strategies International
08:FORECAST A Survey of Oncologists Provides Insight Into the Coming Year The View From the Office: How Community Oncologists See 2008 By Peter Carlin and Don Stark of Market Strategies International While
More informationSutent. Sutent (sunitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.95 Subject: Sutent Page: 1 of 5 Last Review Date: September 15, 2017 Sutent Description Sutent (sunitinib)
More informationREFERENCE CODE GDHC207DFR PUBLICAT ION DATE JUNE 2013 GILOTRIF (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC207DFR PUBLICAT ION DATE JUNE 2013 GILOTRIF (NON-SMALL CELL LUNG CANCER) GILOTRIF (NON-SMALL CELL LUNG CANCER) - Executive Summary Gilotrif: Key Metrics in NSCLC Markets 2022 Gilotrif
More informationREFERENCE CODE GDHC196DFR PUBLICAT ION DATE JUNE 2013 ABRAXANE (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC196DFR PUBLICAT ION DATE JUNE 2013 ABRAXANE (NON-SMALL CELL LUNG CANCER) Executive Summary Abraxane (nab-paclitaxel): Key Metrics in NSCLC Markets 2012 Abraxane Sales US 5EU $98.34m
More informationSutent. Sutent (sunitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.95 Subject: Sutent Page: 1 of 6 Last Review Date: March 16, 2018 Sutent Description Sutent (sunitinib)
More informationSynribo (Chronic Myeloid Leukemia)
Synribo (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022 GDHC1141DFR / Published May 2013 Executive Summary Synribo (omacetaxine mepesuccinate): Key Metrics in CML Markets 2012 Synribo Sales
More informationREFERENCE CODE GDHC199DFR PUBLICAT ION DATE JUNE 2013 XALKORI (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC199DFR PUBLICAT ION DATE JUNE 2013 XALKORI (NON-SMALL CELL LUNG CANCER) Executive Summary Xalkori (crizotinib): Key Metrics in NSCLC Markets 2012 Xalkori Sales US 5EU Japan China India
More informationPatient Leader Education Summit. Precision Medicine: Today and Tomorrow March 31, 2017
Patient Leader Education Summit Precision Medicine: Today and Tomorrow March 31, 2017 Precision Medicine: Presentation Outline Agenda What is a Precision Medicine What is its clinical value Overview of
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationREFERENCE CODE GDHC200DFR PUBLICAT ION DATE JUNE 2013 AVASTIN (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC200DFR PUBLICAT ION DATE JUNE 2013 AVASTIN (NON-SMALL CELL LUNG CANCER) AVASTIN (NON-SMALL CELL LUNG CANCER) - Executive Summary Avastin (bevacizumab): Key Metrics in NSCLC Markets 2012
More informationPPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM
HEMATOLOGY ONCOLOGY PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM COMMITTED TO ADVANCING DRUG DEVELOPMENT IN ONCOLOGY $ MARKETPLACE COMPLEXITIES increasingly competitive marketplace and rising cost pressures
More informationAzacitidine Vidaza Non-transplant myelodysplastic syndrome Funded Funded Funded Funded Funded Funded Not Funded
Provincial Fundin Summary The interim Joint Oncoloy Dru Review (ijodr) was the precursor oncoloy dru review process prior to pcodr, which provided evidence-based recommendation for cancer treatments from
More informationISSUE BRIEF Conference on Clinical Cancer Research November 2014
ISSUE BRIEF Conference on Clinical Cancer Research November 2014 Introduction Considerations for Summary Review of Supplemental NDA/BLA Submissions in Oncology Rachel Sherman, Principal, Drug and Biological
More informationChronic Myeloid Leukemia (CML)
Chronic Myeloid Leukemia (CML) Japan Drug Forecast and Market Analysis to 2022 GDHC1088CFR / Published April 2013 Executive Summary Sales for CML in Japan The Japan CML therapeutics market in the 7MM is
More informationOncology Market Opportunities, Strategies, and Forecasts, 2006 to Oncology. Picture by Susie Eustis MOUNTAINS OF OPPORTUNITY
Oncology Market Opportunities, Strategies, and Forecasts, 2006 to 2012 Oncology Picture by Susie Eustis MOUNTAINS OF OPPORTUNITY WinterGreen Research, Inc. Lexington, Massachusetts www.wintergreenresearch.com
More informationHow Personalized Medicine is Changing the Biopharmaceutical Marketplace
How Personalized Medicine is Changing the Biopharmaceutical Marketplace Marc Chioda, PharmD Associate Medical Director, Pfizer Oncology. Presentation to the Cancer Action Coalition of Virginia January
More informationPublication Plan 2017
Publication Plan 2017 A passion for turning high quality, independent research insights into actionable commercial intelligence. Why Spherix Global Insights? Our independent reports are designed, developed,
More informationOncology Pipeline Analytics
Oncology Pipeline Analytics Trials, Drug Classes, Indications, Correlations and Strategies Report Brochure O n c o l o g y P i p e l i n e A n a l y t i c s Greystone Research Associates is pleased to
More informationOncology Treatment Trends and Implications for Future Drug Development In China. Presented by Stephanie Hawthorne 16 April 2013
Oncology Treatment Trends and Implications for Future Drug Development In China Presented by Stephanie Hawthorne 16 April 2013 Economic development, demographic shift, regulatory environment change, industry
More informationAfinitor. Afinitor and Afinitor Disperz (everolimus) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.62 Subject: Afinitor Page: 1 of 7 Last Review Date: June 22, 2017 Afinitor Description Afinitor and
More informationONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE
CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES ONCOLOGY: WHEN EXPERTISE, EXPERIENCE AND DATA MATTER. KANTAR HEALTH ONCOLOGY SOLUTIONS: FOCUSED I DEDICATED I HERITAGE AT KANTAR HEALTH, ONCOLOGY
More informationPRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019
MONDAY, JUNE 3, 2019 7:30 AM - 9:15 AM HIGHLIGHTS OF THE DAY 8:00 AM - 9:00 AM S 8:00 AM - 9:15 AM S S 8:00 AM - 11:00 AM S Highlights of the Day Session II Bringing New and Innovative Glioblastoma Treatments
More informationPrevention and Treatment of Prostate Cancer: Technologies and Global Markets March Usha Nagavarapu. Report # PHM113B
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets March 2017 Usha Nagavarapu Report # PHM113B Table of Contents Chapter 1 Introduction... 1 Introduction... 1 Study goals and
More informationHOW TO MAXIMIZE PATIENT RECRUITMENT IN ONCOLOGY TRIALS A BIOPHARMA DIVE PLAYBOOK
HOW TO MAXIMIZE PATIENT RECRUITMENT IN ONCOLOGY TRIALS A BIOPHARMA DIVE PLAYBOOK Over the last several decades, patient recruitment for clinical trials has remained a major barrier to rapid execution of
More informationCommissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on
More informationPass the Buck: The New Face of Oncology Formulary Management
Pass the Buck: The New Face of Oncology Formulary Management June 16, 2016 Agenda U.S. Oncology Market Trends Prescriber Incentive Pathway Overview Oncology TA Deep-Dive Non-Small Cell Lung Cancer Multiple
More informationWhitePaper. Oncology: The Disease, the Dynamics and the Difficulties of Global Marketing Research
WhitePaper Oncology: The Disease, the Dynamics and the Difficulties of Global Marketing Research Introduction The World Health Organisation estimates that the incidence of cancer could increase by 50%
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationGenetics in Cancer Therapy. Raju Kucherlapati, Ph.D. Harvard Medical School
Genetics in Cancer Therapy Raju Kucherlapati, Ph.D. Harvard Medical School RK Financial interests I do not intend to discuss an off-label use of a product during this activity AVEO Pharmaceuticals KEW
More informationORAL ONCOLOGY CRITERIA
ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year REVIEW CRITERIA: Drug Name Indication & Dosage Age Limit Quantity per day AFINITOR (everolimus) AFINITOR DISPERZ (everolimus)
More informationICLIO National Conference
ICLIO National Conference Immuno-oncology In The Clinic Today Lee Schwartzberg, MD, FACP Executive Director, West Cancer Center Chief, Division of Hematology/Oncology University of Tennessee Health Science
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationVectibix. Vectibix (panitumumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.85 Subject: Vectibix Page: 1 of 5 Last Review Date: December 2, 2016 Vectibix Description Vectibix
More informationORAL ONCOLOGY CRITERIA
ORAL ONCOLOGY CRITERIA LENGTH OF AUTHORIZATION: Varies; Maximum of one year REVIEW CRITERIA: Drug Name Indication & Dosage Age Limit Quantity per day AFINITOR (everolimus) AFINITOR DISPERZ (everolimus)
More informationNational Cancer Drugs Fund List - Approved
National Cancer Drugs Fund List - Approved DRUG Abiraterone Aflibercet Albumin Bound Paclitaxel Axitinib CDF INDICATION (EXCLUDING APPROVED CRITERIA ) Metastatic Prostate Cancer Metastatic Colorectal Cancer
More informationImmuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The
More informationTargeted Medicine and Molecular Therapeutics. Angus McIntyre, M.D. Medical Oncologist, Addison Gilbert Hospital and Beverly Hospital October 6, 2009
Targeted Medicine and Molecular Therapeutics Angus McIntyre, M.D. Medical Oncologist, Addison Gilbert Hospital and Beverly Hospital October 6, 2009 Approaches to Cancer Prevention Screening and early diagnosis
More informationOncology Market Forecast To 2013
Oncology Market Forecast To 2013 How do you uncover the threats and opportunities that your oncology drug will face this year, next year and each year after that? Our new report answers your questions
More informationGleevec. Gleevec (imatinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.74 Subject: Gleevec Page: 1 of 6 Last Review Date: June 24, 2016 Gleevec Description Gleevec (imatinib)
More informationMATCHMAKING IN ONCOLOGY CHALLENGES AND COMBINATION STRATEGY FOR NOVEL TARGETED AGENTS
MATCHMAKING IN ONCOLOGY CHALLENGES AND COMBINATION STRATEGY FOR NOVEL TARGETED AGENTS DR. RACHEL E. LAING*, OLIVIER LESUEUR*, STAN HOPKINS AND DR. SEAN X. HU MAY 2012 Recent advances in oncology, such
More informationIncyte Reports 2014 Second Quarter Financial Results and Updates Shareholders on Key Clinical Programs
Print Page Close Window Press Release Incyte Reports 2014 Second Quarter Financial Results and Updates Shareholders on Key Clinical Programs $84.0 million of 2014 second quarter net product revenues from
More informationHEALTHCARE CLAIMS TRACKER A FOCUS ON ONCOLOGY CLAIMS. September 2018 For the period January 2017 December 2017
HEALTHCARE A FOCUS ON CLAIMS September 208 For the period January 207 December 207 INTRODUCTION Cancer is one of the leading causes of death both globally and in South Africa. Worldwide, one in seven deaths
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Stivarga) Reference Number: CP.PHAR.107 Effective Date: 12.01.12 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of
More informationTasigna. Tasigna (nilotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.77 Subject: Tasigna Page: 1 of 6 Last Review Date: March 16, 2018 Tasigna Description Tasigna (nilotinib)
More informationTasigna. Tasigna (nilotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.77 Subject: Tasigna Page: 1of 5 Last Review Date: September 15, 2017 Tasigna Description Tasigna (nilotinib)
More informationSAMPLE. Rencarex (Renal Cell Carcinoma)- Analysis and Forecasts to Reference Code: GDHC0004RCCDVR Publication Date: March 2012
Rencarex (Renal Cell Carcinoma)- Analysis and Forecasts to Reference Code: GDHC0004RCCDVR Publication Date: March 2012 The Renal Cell Carcinoma (RCC) Disease Therapeutics Market GlobalData s analysis suggests
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Afinitor, Afinitor Disperz) Reference Number: CP.PHAR.63 Effective Date: 06.01.11 Last Review Date: 08.18 Line of Business: Commercial Coding Implications Revision Log See Important Reminder
More informationJP Morgan Healthcare Conference
JP Morgan Healthcare Conference Lamberto Andreotti Chief Executive Officer January 14, 2014 Forward-Looking Information During this meeting, we will make statements about the Company s future plans and
More informationStivarga. Stivarga (regorafenib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.26 Subject: Stivarga Page: 1 of 5 Last Review Date: September 15, 2017 Stivarga Description Stivarga
More informationDS-8201 Strategic Collaboration
DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections
More informationREFERENCE CODE GDHC465DFR PUBLICAT ION DATE SEPTEMBER 2014 KADCYLA (HER2-POSITIVE BREAST CANCER) - FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC465DFR PUBLICAT ION DATE SEPTEMBER 2014 KADCYLA (HER2-POSITIVE BREAST CANCER) - Executive Summary The table below presents the key metrics for Kadcyla for human epidermal growth factor
More informationMedivation, Inc. (MDVN-NASDAQ)
March 19, 2015 Medivation, Inc. (MDVN-NASDAQ) NEUTRAL Current Recommendation Prior Recommendation Outperform Date of Last Change 03/25/2014 Current Price (03/18/15) $132.19 Target Price $139.00 SUMMARY
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationSummary of Strategic Competitive Analysis and Publication Planning
Summary of Strategic Competitive Analysis and Publication Planning Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Briefing
More information2016 Year-End Results and Conference Call. March 14, 2017
2016 Year-End Results and Conference Call March 14, 2017 Forward Looking Statement This communication contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform
More informationSPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationNEWS RELEASE Media Contact: Megan Pace Investor Contact: Kathee Littrell Patient Inquiries: Ajanta Horan
NEWS RELEASE Media Contact: Megan Pace 650-467-7334 Investor Contact: Kathee Littrell 650-225-1034 Patient Inquiries: Ajanta Horan 650-467-1741 GENENTECH RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR
More informationStrategy at Work. MedStar Health. Engaging people, improving performance
Strategy at Work MedStar Health Engaging people, improving performance About MedStar Health A $3.1 billion nonprofit health care organization formed in 1998 Headquartered in Columbia, MD Operates eight
More informationREFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC295DFR PUBLICATION DATE NOVEMBER 2013 ELIDEL (ATOPIC DERMATITIS) Executive Summary The below mentioned table presents key metrics for Elidel in the major pharmaceutical markets: the
More informationInfinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results
Infinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results Heat Shock Protein 90 Program Continues to Advance Toward Potential Registration Trial CAMBRIDGE, Mass.,
More informationBayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Tasigna) Reference Number: CP.PHAR.76 Effective Date: 09.01.11 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More information1.5. Research Areas Treatment Selection
1.5. Research Areas Cancer biomarker research embraces many areas of study, including tumorigenesis, metastasis, clinical trial and surrogate endpoints, cell isolation, target identification, drug resistance,
More information2018 Bank of America Merrill Lynch Healthcare Conference
CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD PURSUITS IN SCIENCE 2018 Bank of America Merrill Lynch Healthcare Conference May 16, 2018 Forward-Looking Statements and Adjusted Financial Information
More informationU.S. FDA Approves New Indication for the Use of XTANDI (enzalutamide) Capsules for Patients with Metastatic Castration-Resistant Prostate Cancer
Astellas Contact: Medivation Contact: Tyler Marciniak Rick Bierly Director, Communications and Advocacy Chief Financial Officer (847) 736-7145 (415) 543-3470 tyler.marciniak@astellas.com Anne Bowdidge
More informationClinical Policy: Everolimus (Afinitor, Afinitor Disperz) Reference Number: PA.CP.PHAR.63
Clinical Policy: (Afinitor, Afinitor Disperz) Reference Number: PA.CP.PHAR.63 Effective Date: 01/18 Last Review Date: Coding Implications Revision Log Description The intent of the criteria is to ensure
More informationBuilding a Premier Oncology Biotech
Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation
More informationAccelerate Your Research with Conversant Bio
Imagination has given us the steam engine, the telephone, the talkingmachine and the automobile, for these things had to be dreamed of before they became realities. So I believe that dreams... are likely
More informationPharmacy Management Drug Policy
SUBJECT: Oncology Clinical Review Prior Authorization (Oncology-CRPA) Rx Drugs POLICY NUMBER: Pharmacy-33 EFFECTIVE DATE: 10/13 LAST REVIEW DATE: 09/05/2018 If the member s subscriber contract excludes
More information6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
More informationLung Cancer Screening
Lung Cancer Screening v Lung Cancer: America s leading cancer killer Annual US cancer mortality 158,040 221,000 new diagnoses in US 4,100 14,180 27,540 Lung 40,560 40,730 49,700 Cervix Ovary Prostate Pancreas
More informationNATIONAL CANCER CONTROL PROGRAMME NATIONAL STRATEGY FOR THE SAFE ADMINISTATION OF CANCER DRUGS
NATIONAL CANCER CONTROL PROGRAMME NATIONAL STRATEGY FOR THE SAFE ADMINISTATION OF CANCER DRUGS Dr Susan O Reilly MB, FRCPC, FRCPI National Director National Cancer Control Programme IMSN Networking for
More informationPharmacy Medical Necessity Guidelines: Oral Cancer Medications
Pharmacy Medical Necessity Guidelines: Effective: February 18, 2019 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED)
More informationFirst phase III data on Roche s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress
Media Release Basel, 03 October 2016 First phase III data on Roche s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress Superiority results from the phase
More informationGlobal Strategic Partners Merck and Pfizer Finalize Agreement to Co-Promote XALKORI (crizotinib)
Merck Media: Markus Talanow +49 6151 72 7144 Investor Relations: +49 6151 72 3321 Pfizer Media: Sally Beatty +1 212 733 6566 Investor Relations: Ryan Crowe +1 212 733 8160 News Release April 7, 2015 Not
More informationPresentation to AGM 9 November Deborah Rathjen CEO & Managing Director
Presentation to AGM 9 November 2011 Deborah Rathjen CEO & Managing Director Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward looking" statements within the
More informationPersonalized Medicine Disruptive Technology? David Logan Senior Vice President, Commercial Genomic Health Inc
1 Personalized Medicine Disruptive Technology? David Logan Senior Vice President, Commercial Genomic Health Inc Safe Harbor Statement This presentation contains forward-looking statements within the meaning
More informationPharmacy Management Drug Policy
SUBJECT: Oncology Clinical Review Prior Authorization (Oncology-CRPA) Rx Drugs POLICY NUMBER: Pharmacy-33 EFFECTIVE DATE: 10/13 LAST REVIEW DATE: 11/12/2018 If the member s subscriber contract excludes
More informationEuropean Experience and Perspective on Assessing Value for Oncology Products. Michael Drummond Centre for Health Economics, University of York
European Experience and Perspective on Assessing Value for Oncology Products Michael Drummond Centre for Health Economics, University of York Outline of Presentation The European landscape on access to
More informationSubmission to the Senate Inquiry into the availability of new, innovative and specialist cancer drugs in Australia Executive Summary
Submission to the Senate Inquiry into the availability of new, innovative and specialist cancer drugs in Australia Prepared by the Cancer Drugs Alliance, February 2015 Executive Summary Australia has the
More informationPharmacy Management Drug Policy
SUBJECT: Oncology Clinical Review Prior Authorization (Oncology-CRPA) Rx Drugs POLICY NUMBER: Pharmacy-33 EFFECTIVE DATE: 10/13 LAST REVIEW DATE: 03/22/2018 If the member s subscriber contract excludes
More informationCredit Suisse 27 th Annual Healthcare Conference
CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD PURSUITS IN SCIENCE Credit Suisse 27 th Annual Healthcare Conference November 14, 2018 Forward-Looking Statements and Adjusted Financial Information This
More informationPascal Soriot, Head of Strategic Marketing
Workshop Marketing a cancer drug Pascal Soriot, Head of Strategic Marketing Trends in the oncology market Europe/ RoW compared to US Marketing cancer drugs successfully Leveraging 1 st mover advantage
More informationSU2C TOP SCIENCE ACCOMPLISHMENTS
SU2C TOP SCIENCE ACCOMPLISHMENTS INTRODUCTION Since our founding in 2008, Stand Up To Cancer has funded 87 team science projects, with budgets ranging from $250,000 for a short research project to over
More informationCancer statistics 12 million people diagnosed each year 8 million people die each year from cancer Cancer is on increase mostly due to growing and age
Cancer statistics 12 million people diagnosed each year 8 million people die each year from cancer Cancer is on increase mostly due to growing and ageing population Malvezzi, M. et al. (2013) European
More informationThe Oncology Drug Marketplace: Trends in Discounting and Site of Care
The Oncology Drug Marketplace: Trends in Discounting and Site of Care DECEMBER 2017 PREPARED BY: Aaron Vandervelde avandervelde@thinkbrg.com 202.480.2661 Eleanor Blalock eblalock@thinkbrg.com 202.480.2772
More informationErbitux. Erbitux (cetuximab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.84 Subject: Erbitux Page: 1 of 6 Last Review Date: December 2, 2016 Erbitux Description Erbitux (cetuximab)
More informationNEWS RELEASE Media Contact: Krysta Pellegrino (650) Investor Contact: Sue Morris (650) Advocacy Contact: Kristin Reed (650)
NEWS RELEASE Media Contact: Krysta Pellegrino (650) 225-8226 Investor Contact: Sue Morris (650) 225-6523 Advocacy Contact: Kristin Reed (650) 467-9831 FDA APPROVES AVASTIN IN COMBINATION WITH CHEMOTHERAPY
More information2018 Edition The Current Landscape of Genetic Testing
2018 Edition The Current Landscape of Genetic Testing Market growth, reimbursement trends, challenges and opportunities November April 20182017 EXECUTIVE SUMMARY Concert Genetics is a software and managed
More informationCLINICAL RESEARCH IN GEORGIA UPDATE. Nancy M. Paris, MS, FACHE President, Georgia CORE September 6, 2014
CLINICAL RESEARCH IN GEORGIA UPDATE Nancy M. Paris, MS, FACHE President, Georgia CORE September 6, 2014 Georgia CORE is a public-private partnership dedicated to generating collaborative resources for
More informationGastric Cancer. Introduction
Gastric Cancer Introduction Despite advances in surgery and the use of multimodality therapy, survival outcomes remain poor for gastric cancer patients. There is an urgent need for more effective therapies
More information